RTP Mobile Logo

This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast and colon cancer.

Many controversies and clinical questions currently surround the management of localized breast and colorectal cancers. Central among these is the use and effectiveness of available biomarkers in guiding decision-making regarding adjuvant treatment. This CME program brings together leading clinical investigators in the fields of breast and colon cancer to provide perspectives on the development, assessment and clinical utility of select genomic assays and biomarkers that are available to assist clinicians managing these highly prevalent diseases. By reviewing available clinical trial data and relevant case scenarios, this initiative will help learners to ascertain the effectiveness of diagnostic, prognostic and predictive biomarkers as they relate to the adjuvant treatment of breast and/or colorectal cancer.


  • Recognize the evolving application of biomarkers and multigene assays in the management of breast and colon cancer, and effectively use these tools to refine or individualize treatment plans for selected patients.
  • Determine the utility of the Oncotype DX® Recurrence Score® assay in counseling patients with ER-positive early breast cancer about their risk of recurrence and the potential benefits of adjuvant chemotherapy.
  • Counsel patients with Stage II and Stage III colon cancer about their individual risk of recurrence based on clinical, pathologic and genomic biomarkers, and consider adjuvant therapeutic options based on an evaluation of this information.
  • Assess the utility of the Oncotype DX DCIS Score assay in counseling patients with DCIS about their risk of recurrence and the potential benefits of radiation therapy.
  • Evaluate the evidence-based benefits of adjuvant chemotherapy for patients with Stage II colon cancer and the risks and benefits of oxaliplatin-containing chemotherapy in lower-risk Stage III disease.
  • Counsel appropriately selected patients about participation in ongoing clinical trials.


CME credit is no longer available for this issue


CME credit is no longer available for this issue

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and his spouse/partner) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Steven R Alberts, MD, MPH
Chair, Division of Medical Oncology
Professor of Oncology
Mayo Clinic
Rochester, Minnesota

Data and Safety Monitoring Board: BioSphere Medical, Pfizer Inc.

Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

No financial interests or affiliations to disclose.

Joseph A Sparano, MD
Professor of Medicine and Women’s Health
Albert Einstein College of Medicine
Associate Chairman, Department of Oncology
Montefiore Medical Center
Bronx, New York

Advisory Committee: Amgen Inc, Celldex Therapeutics, Curis Inc, Eisai Inc, Johnson & Johnson Pharmaceuticals, MetaStat Inc, Pfizer Inc; Consulting Agreement: Genentech BioOncology; Contracted Research: ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company; Paid Research: Merck, Takeda Oncology.

Alan P Venook, MD
Professor of Clinical Medicine
University of California, San Francisco
San Francisco, California

Advisory Committee: Bayer HealthCare Pharmaceuticals; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Sanofi; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Lilly, Onyx Pharmaceuticals, an Amgen subsidiary.

Norman Wolmark, MD
Chairman, National Surgical Adjuvant Breast and Bowel Project
Professor of Surgery
Temple University School of Medicine
Philadelphia, Pennsylvania

Advisory Committee: Genentech BioOncology; Other Remunerated Activities: Sanofi.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Genomic Health Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: July 2015
Expiration date: July 2016